Witjes - Figure 12
High-risk disease recommendation
FIG. 12: Concerning therapy for high-risk patients, the advice is also similar and clear in both guidelines: these patients should be treated with maintenance BCG.[1,2]
References
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer; unabridged version: American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. Linthicum, MD: American Urological Association; 2016 https://www.auanet.org/documents/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf Accessed August 3, 2017.
Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447−61 http://dx.doi.org/10.1016/j.eururo.2016.05.041